All In Biotech

Drug Trial Radar · NCT07239674

Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC

Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in Intermediate-to-High Risk Differentiated Thyroid Cancer After Surgery: A National Multicenter, Open-Label, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

646

Planned (sponsor's estimate)

Start

Nov 30, 2025

Primary completion

Nov 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
West China Tianfu Hospital; Shang Jin Hospital of West China Hospital,Sichuan University; Sichuan Academy of Medical Sciences; First Affiliated Hospital of Guangxi Medical University; First Affiliated Hospital of Kunming Medical University; Xijing Hospital of Airforce Medical University; Sir Run Run Shaw Hospital; First Affiliated Hospital of Chongqing Medical University; The Affiliated Hospital Of Guizhou Medical University; The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Lanzhou University; Qinghai Province Fifth People's Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The First Affiliated Hospital of Shanxi Medical University; General Hospital of Ningxia Medical University; Yantai Yuhuangding Hospital; Sun Yat-Sen University Cancer Center; Zhongnan Hospital
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The global incidence of Differentiated Thyroid Cancer (DTC) is rising. While surgery followed by TSH suppression is the standard of care, achieving target TSH levels with levothyroxine (L-T4) monotherapy remains challenging, with only 25-70% of intermediate/high-risk patients attaining it within 6-8 months. This therapeutic dilemma stems from three key issues: impaired T4-to-T3 conversion due to DIO2 polymorphisms, the non-physiological hormone ratio of T4 monotherapy, and L-T4's narrow therapeutic window. This often results in an "under- versus over-suppression" paradox, increasing risks of recurrence, atrial fibrillation, and osteoporosis. Combining L-T4 with desiccated thyroid extract (DTE; T4:T3 ≈ 4:1) may overcome these limitations by bypassing DIO2 defects and providing a more physiological hormone profile, thereby potentially improving TSH control while mitigating side effects. Supported by the 2023 Chinese guidelines and our promising pilot data (82% cumulative target attainment at a median of 1.4 months), we propose a two-stage national study: a multicenter cohort study followed by a randomized trial, to generate high-level evidence for this combination therapy in high-risk DTC.

Conditions

  • Intermediate-to-High Risk Differentiated Thyroid Cancer

Interventions

  • desiccated thyroid extract (DTE)+levothyroxine (L-T4)Drug

    Desiccated thyroid extract (DTE) is a dry preparation obtained from animal thyroid glands that contains both thyroxine (T4) and triiodothyronine (T3) in an approximately 4:1 ratio, closely matching the physiological hormone profile secreted by the human thyroid. Combining DTE with levothyroxine (L-T4) may overcome current therapeutic bottlenecks. First, L-T4 given in adequate doses provides the major T4-mediated TSH suppression, while the small amount of T3 supplied by DTE acts directly on pituitary thyrotrophs, bypassing impaired DIO2 conversion; this pharmacodynamic synergy yields tighter TSH control, steadier serum levels, and fewer thyrotoxic side-effects. Second, because thyroid-hormone receptor isoforms are differentially expressed across tissues and display distinct T4/T3 affinities, the combination allows finer tuning of thyroid hormone signaling-maintaining adequate tumor suppression while attenuating adverse cardiac and skeletal effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of adequate TSH suppressionTime frame: 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment
  2. Time to TSH suppression targetTime frame: 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.